1. Home
  2. MGN vs ARTL Comparison

MGN vs ARTL Comparison

Compare MGN & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MGN

Megan Holdings Limited Ordinary Shares

HOLD

Current Price

$0.10

Market Cap

2.6M

Sector

N/A

ML Signal

HOLD

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$0.75

Market Cap

2.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGN
ARTL
Founded
2020
2011
Country
Malaysia
United States
Employees
4
7
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6M
2.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MGN
ARTL
Price
$0.10
$0.75
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
N/A
AVG Volume (30 Days)
32.6M
142.1K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$32.33
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.06
$0.71
52 Week High
$5.18
$19.91

Technical Indicators

Market Signals
Indicator
MGN
ARTL
Relative Strength Index (RSI) 47.28 27.15
Support Level N/A $0.71
Resistance Level $0.16 $1.87
Average True Range (ATR) 0.03 0.07
MACD 0.01 -0.01
Stochastic Oscillator 20.29 10.32

Price Performance

Historical Comparison
MGN
ARTL

About MGN Megan Holdings Limited Ordinary Shares

Megan Holdings Ltd is principally engaged in the development, construction and maintenance of aquaculture farms and related works. Its operations are based in Malaysia. The company's operating segments include: Aquaculture and agriculture; Industrial solutions; and Investment in marketable securities. It derives maximum revenue from Aquaculture and agriculture, which involves development, construction, and maintenance of aquaculture and agriculture farms and related works.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: